Adjunctive probiotic therapy sustains symptom relief in gastroesophageal reflux disease through gut microbiome-metabolome remodeling
mSystems · 2026
DOI: 10.1128/msystems.01568-25 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift mSystems, 2026. Verfasst von Yingmeng Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China. Hauptthemen laut MEDLINE: Probiotics, Gastroesophageal Reflux, Gastrointestinal Microbiome, Metabolome. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Inner Mongolia Autonomous Region Science and Technology Leading Talent Team Project, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Proton pump inhibitors (PPIs) are standard therapy for gastroesophageal reflux disease (GERD), but long-term use causes dysbiosis, gastrointestinal side effects, and symptom relapse after discontinuation. Probiotics may offer adjunctive benefits by modulating the gut ecosystem. The study aimed to evaluate the efficacy of a multi-strain probiotic (Lihuo) with rabeprazole in GERD and its impact on gut microbiota and metabolome. A randomized, double-blind, placebo-controlled trial was conducted in 120 GERD patients assigned to receive rabeprazole with either Lihuo ( n = 64) or placebo ( n = 56) for 8 weeks, followed by 4 weeks of probiotic or placebo alone. The primary outcome was change in the Reflux Disease Questionnaire (RDQ) score. Secondary outcomes included Gastrointestinal Symptom Rating Scale, endoscopic healing, and multi-omics profiling (shotgun metagenomics, phageome, and untargeted/targeted metabolomics). Compared with the placebo group, the probiotic group exhibited a pronounced 36.51% reduction in RDQ scores after 12 weeks of intervention ( P = 0.017), alongside a higher numerical endoscopic healing rate (36.84% vs 12.50%; P = 0.365). Metagenomics revealed enrichment of Bifidobacterium animalis , Lactiplantibacillus plantarum , and Clostridium sp900540255, with reductions in Bacteroides uniformis and Clostridium Q fessum . Metabolomics showed increased γ-aminobutyric acid, succinate, citrulline, and short-chain fatty acids levels, with interesting microbe-metabolite correlations such as Bifidobacterium animalis -γ-aminobutyric acid and Bacteroides fragilis -succinate ( r ≥ 0.30, P < 0.01). Our findings support that adjunctive probiotic therapy sustains post-PPI symptom relief, associated with targeted modulation of gut microbiota and bioactive metabolites. IMPORTANCE Long-term proton pump inhibitor use in gastroesophageal reflux disease (GERD) may disrupt gut microbiota and cause symptom relapse after discontinuation. We found that adjunctive probiotic therapy sustained reflux reduction post-proton pump inhibitor. Probiotic use enriched beneficial taxa ( Bifidobacterium and Lactiplantibacillus plantarum ) and increased γ-aminobutyric acid, succinate, citrulline, and short-chain fatty acids. Strong correlations linked microbial shifts to metabolic and clinical improvements. This study demonstrates that adjunctive probiotic therapy enhances symptom control and supports microbial-metabolic homeostasis in GERD. CLINICAL TRIALS This study is registered with the Chinese Clinial Trial Registry as ChiCTR2000038409 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China.
- Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China.
- Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China.
- Collaborative Innovative Center of Ministry of Education for Lactic Acid Bacteria and Fermented Dairy Products, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China.
- State Key Laboratory for the Modernization of Classical and Famous Prescriptions of Chinese Medicine, Nanchang, China.
- Research and Development Department, Jiangzhong Pharmaceutical Co., Ltd., Nanchang, China.
ORCID-Profile: Yingmeng Li, Qiong Li, Keyu Quan, Yong Xie, Zhihong Sun, Nonghua Lu, Weifeng Zhu, Wenjun Liu, Heping Zhang
Förderung
- the Inner Mongolia Autonomous Region Science and Technology Leading Talent Team Project
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- the Earmarked Fund for China Agriculture Research System
- the China National Postdoctoral Program for Innovative Talents
Zitieren
APA
Li, Y., Li, Q., Quan, K., Xie, Y., Yang, N., Ma, T., Zheng, L., Zhou, W., Li, Y., Jin, H., Sun, Z., Chen, Y., Kwok, L. Y., Lu, N., Zhu, W., Liu, W., & Zhang, H. (2026). Adjunctive probiotic therapy sustains symptom relief in gastroesophageal reflux disease through gut microbiome-metabolome remodeling. mSystems. https://doi.org/10.1128/msystems.01568-25
Vancouver
Li Y, Li Q, Quan K, Xie Y, Yang N, Ma T, et al. Adjunctive probiotic therapy sustains symptom relief in gastroesophageal reflux disease through gut microbiome-metabolome remodeling. mSystems. 2026. doi:10.1128/msystems.01568-25
BibTeX
@article{Li2026,
author = {Li, Yingmeng and Li, Qiong and Quan, Keyu and Xie, Yong and Yang, Ni and Ma, Teng and Zheng, Longjin and Zhou, Wei and Li, Yalin and Jin, Hao and Sun, Zhihong and Chen, Yongfu and Kwok, Lai-Yu and Lu, Nonghua and Zhu, Weifeng and Liu, Wenjun and Zhang, Heping},
title = {Adjunctive probiotic therapy sustains symptom relief in gastroesophageal reflux disease through gut microbiome-metabolome remodeling},
journal = {mSystems},
year = {2026},
doi = {10.1128/msystems.01568-25}
}
EUVIMED